Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.52 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA4 | P22748 | 4/20 | 0.47 |
| ▸ | CA6 | P23280 | 4/20 | 0.47 |
| ▸ | CA5A | P35218 | 4/20 | 0.47 |
| ▸ | CA7 | P43166 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29657545 | 1.00 | TSHR (0.57) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL19954139 | 1.00 | TSHR (0.57) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL15030982 | 1.00 | TSHR (0.57) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL14248230 | 1.00 | TSHR (0.57) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL10228174 | 1.00 | TSHR (0.57) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL19415602 | 1.00 | TSHR (0.57) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL14644614 | 1.00 | TSHR (0.57) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL16730395 | 1.00 | TSHR (0.57) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL16730397 | 1.00 | TSHR (0.57) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL14081703 | 0.93 | TSHR (0.58) | TSHRSLC5A2SLC5A1PTPN1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2023-01-10 | — | — | US | disclosed |
| US-20210388016-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| US-20210388015-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| US-20210388015-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| US-20210388016-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| US-10913762-B2 | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2021-02-09 | — | — | US | disclosed |
| US-10913762-B2 | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2021-02-09 | — | — | US | disclosed |
| US-20200331946-A1 | PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF | EMMENNAR PHARMA PRIVATE LIMITED, (IN) | 2020-10-22 | — | — | US | disclosed |
| US-10703772-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2020-07-07 | — | — | US | disclosed |
| US-10703772-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2020-07-07 | — | — | US | disclosed |
| US-20140228303-A1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC LTD (IN) | 2014-08-14 | — | — | US | disclosed |
| EP-2676965-A1 | ARYL GLYCOSIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | Shanghai Yingli Science And Technology Co., Ltd (CN) | 2013-12-25 | — | — | EP | disclosed |
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| WO-2008002824-A1 | CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | TSHR 4409/4885SLC5A2 2/4885SLC5A1 1/4885 |
| US-10703772-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | SLC5A2, SLC5A1, SLC2A4 | TSHR 4670/4885SLC5A2 1/4885SLC5A1 2/4885 |
| US-20140228303-A1 | NOVEL SGLT INHIBITORS | SLC5A1, SLC5A2, SLC2A1 | TSHR 3621/4885SLC5A2 2/4885SLC5A1 1/4885 |
| US-20210388016-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, UGGT1 | TSHR 4290/4885SLC5A2 1/4885SLC5A1 2/4885 |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | SLC5A2, SLC5A1, SLC2A4 | TSHR 4696/4885SLC5A2 1/4885SLC5A1 2/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | TSHR 4409/4885SLC5A2 2/4885SLC5A1 1/4885 |
| US-20210388015-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, UGGT1 | TSHR 4290/4885SLC5A2 1/4885SLC5A1 2/4885 |
| US-10913762-B2 | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof | ALG1, FBP1, DAD1 | TSHR 4569/4885SLC5A2 98/4885SLC5A1 12/4885 |
| US-20200331946-A1 | PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF | SLC5A2, SLC5A1, SLC2A4 | TSHR 4696/4885SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.